DTIL Company Profile and Key Details
Precision BioSciences, Inc.
DTIL Stock Price Chart
Stock Price Today
Precision BioSciences, Inc. (DTIL) stock surged +7.28%, trading at $5.01 on NASDAQ, up from the previous close of $4.67. The stock opened at $4.71, fluctuating between $4.71 and $5.14 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Company Information
| Employees | 108 |
| Beta | 1.69 |
| Sales or Revenue | $48.73M |
| 5Y Sales Change% | 0.905% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Precision BioSciences, Inc. (NASDAQ: DTIL) stock price is $5.01 in the last trading session. During the trading session, DTIL stock reached the peak price of $5.14 while $4.71 was the lowest point it dropped to. The percentage change in DTIL stock occurred in the recent session was 7.28% while the dollar amount for the price change in DTIL stock was $0.34.
The NASDAQ listed DTIL is part of Biotechnology industry that operates in the broader Healthcare sector. Precision BioSciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Heather King
Director of Marketing Communications & PR
Ms. Juli Blanche
Chief People Officer
Dr. Derek Jantz Ph.D.
Co-Founder & Chief Science Advisor
Mr. John Alexander Kelly
Chief Financial Officer
Mei Burris
Director of Investor Relations & Fin.
Mr. Bruce Stevens
Vice President of Quality & Compliance
Mr. Shane Barton
Vice President, Corporation Controller & Principal Accounting Officer
Maurissa Messier
Senior Director of Corporation Communications
Mr. Michael Amoroso
Pres, Chief Executive Officer & Director
Dr. Jefferson J. Smith Ph.D.
Co-Founder & Chief Research Officer
Mr. Dario Scimeca
Gen. Counsel & Sec.
Mr. John Alexander Kelly R.Ph.
Chief Financial Officer
DTIL's closing price is 38.78% higher than its 52-week low of $3.61 where as its distance from 52-week high of $19.43 is -74.22%.
Number of DTIL employees currently stands at 108.
Official Website of DTIL is: https://www.precisionbiosciences.com
DTIL could be contacted at phone 919 314 5512 and can also be accessed through its website. DTIL operates from 302 East Pettigrew Street, Durham, NC 27701, United States.
DTIL stock volume for the day was 83.5K shares. The average number of DTIL shares traded daily for last 3 months was 490.44K.
The market value of DTIL currently stands at $39.54M with its latest stock price at $5.01 and 7.89M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com